Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide + dapagliflozin versus dapagliflozin + placebo for liver and ectopic fat reduction in uncontrolled type 2 diabetes mellitus
2016-000574-38Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Exenatide + dapagliflozin with Placebo + dapagliflozin (2 arms). Primary endpoint: Liver fat content at end of treatment. Started Jul 2016; status: completed.
02
Drugs
exenatidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000574-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000574-38.